Review Article
Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective
Table 2
Guidelines for CHC treatment according to Brazilian Ministry of Health.
| | Conditions | Treatment | Duration |
| | Genotype 1 | | | | HCV monoinfected | Sofosbuvir + Simeprevir
OR
Sofosbuvir + Daclatasvir | 12 weeks | HCV monoinfected with Child-Pugh B/C
OR
previously treated by Telaprevir/Boceprevir OR
HIV-HCV coinfection | Sofosbuvir + Daclatasvir | 24 weeks | | Genotype 2 | | | | HCV monoinfected | Sofosbuvir + Ribavirin | 12 weeks | | Genotype 3 | | | | No contraindication for Peg-interferon | Sofosbuvir + Peg-interferon + Ribavirin | 12 weeks | | Contraindication for Peg-interferon | Sofosbuvir + Daclatasvir | 12 weeks | | Genotype 4 | | | | No contraindication for Peg-interferon | Daclatasvir + Peg-interferon + Ribavirin | 24 weeks | | Contraindication for Peg-interferon | Sofosbuvir + Daclatasvir | 12 weeks |
|
|
Source: Brazilian Ministry of Health [16].
|
